1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Tandem Diabetes Care's 1-Year ROIIC % for the quarter that ended in Sep. 2024 was 196.31%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Tandem Diabetes Care's 1-Year ROIIC % or its related term are showing as below:
TNDM's 1-Year ROIIC % is ranked better than 86.78% of 832
companies
in the Medical Devices & Instruments industry
Industry Median: 1.98
vs TNDM: 196.31
Tandem Diabetes Care 1-Year ROIIC % Historical Data
The historical data trend for Tandem Diabetes Care's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tandem Diabetes Care's 1-Year ROIIC %
For the Medical Devices subindustry, Tandem Diabetes Care's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care's 1-Year ROIIC % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's 1-Year ROIIC % falls into.
Tandem Diabetes Care 1-Year ROIIC % Calculation
Tandem Diabetes Care's 1-Year ROIIC % for the quarter that ended in Sep. 2024 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -137.3424 (Sep. 2024) - -219.5061 (Sep. 2023) )
/
( 423.391 (Sep. 2024) - 381.536 (Sep. 2023) )
=
82.1637
/
41.855
=
196.31%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Tandem Diabetes Care (NAS:TNDM) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Tandem Diabetes Care 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Tandem Diabetes Care's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TNDM has been successfully added to your 